Tier 2 — strong

Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial

James I Dower, Johanna M Geleijnse, Lieke Gijsbers, Casper Schalkwijk, Daan Kromhout, Peter C Hollman
The Journal of nutrition 2015 145(7):1459

Bibliography

PubMed
PMID 25972527
DOI
10.3945/jn.115.211888
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled crossover trial; secondary biomarker report
ModelHuman intervention research
Sample37 adults with prehypertension or hypertension
InterventionQuercetin-3-glucoside 160 mg/day, epicatechin 100 mg/day, or placebo
Duration4 weeks per intervention
EndpointsInflammatory measures

What the study showed, in plain terms

Published in 2015, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled crossover trial; secondary biomarker report. Sample/model: 37 adults with prehypertension or hypertension. The exposure or intervention was Quercetin-3-glucoside 160 mg/day, epicatechin 100 mg/day, or placebo. Follow-up or treatment period: 4 weeks per intervention.

Quercetin reduced selected inflammatory and endothelial activation biomarkers, including soluble E-selectin and interleukin-1 beta.

Secondary analyses from the same NCT01691404 trial as the main vascular report; the primary flow-mediated dilation outcome was null. Biomarker changes do not establish fewer cardiovascular events.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin reduced selected inflammatory and endothelial activation biomarkers, including soluble E-selectin and interleukin-1 beta.
  • The recorded outcome domains were Inflammatory measures.
  • The result applies to the tested exposure: Quercetin-3-glucoside 160 mg/day, epicatechin 100 mg/day, or placebo; 4 weeks per intervention.

What this study can and cannot tell us

  • Secondary analyses from the same NCT01691404 trial as the main vascular report; the primary flow-mediated dilation outcome was null. Biomarker changes do not establish fewer cardiovascular events.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial
James I Dower et al. · The American journal of clinical nutrition · 2015
Tier 2
Quercetin, but Not Epicatechin, Decreases Plasma Concentrations of Methylglyoxal in Adults in a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial with Pure Flavonoids
Mathias D G Van den Eynde et al. · The Journal of nutrition · 2018
Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology